What is Eikon Therapeutics, Inc.'s (EIKN) StockRank?

MoatMap's StockRank for Eikon Therapeutics, Inc. (EIKN) is 13/100, with a Strong Sell signal. This is a composite score combining Quality (33), Value (41), and Momentum (25) factor ranks across MoatMap's 20,000+ stock universe.

Does Eikon Therapeutics, Inc. have an economic moat?

Eikon Therapeutics, Inc. (EIKN) has a Quality factor score of 33/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Eikon Therapeutics, Inc. a buy, hold, or sell?

MoatMap's current signal for Eikon Therapeutics, Inc. (EIKN) is Strong Sell, based on a StockRank of 13/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Eikon Therapeutics, Inc. in?

Eikon Therapeutics, Inc. (EIKN) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

EIKN

STRONG SELLREMOVE

Eikon Therapeutics, Inc. · Healthcare · United States · $558M · Avg Vol: $3M/d

StockRank

P/E (TTM)

—

ROE

—

D/E

0.5x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Lacks sufficient public market history, financial transparency, and alignment with our core macro themes to justify inclusion in a concentrated book.

COMPANY DESCRIPTION

Eikon Therapeutics, Inc. is a biotechnology company focused on discovering and developing novel small molecule therapies for oncology and immunology. The company's competitive edge lies in its proprietary Eikon Explorer platform, a live-cell imaging technology that visualizes protein dynamics in real-time, significantly enhancing drug discovery and target validation. It operates as a clinical-stage biotech firm, leveraging this cutting-edge technology to accelerate the development of precision medicines.

FINANCIAL SUMMARY (USD)

Year	2023	2024	2025	CAGR
Revenue	0	0	0	—
EPS	-7.40	-7.45	-6.18	—
Shares	54M	54M	54M	0.0%
Debt	32M	202M	257M	184.8%
Equity	-341M	-572M	-879M	—
Op CF	-191M	-135M	-189M	—
Inv CF	137M	151M	-181M	—
Fin CF	106M	244,000	352M	—

PRICE (1M)+4.8%

SMA 50SMA 200

$9.61

RSI (14)

38.2

SCORE BREAKDOWN

Quality

ROIC

-59.9%10.9

ROE

—N/A

GP/Assets

—N/A

Op. Margin

0.0%40.4

FCF/Assets

—N/A

Piotroski

—28.7

Int. Cover

-50.0x6.4

D/E Ratio

0.46x33.5

Current Ratio

11.75x89.3

Value

P/E (TTM)

—N/A

EV/EBITDA

-0.7x63.7

P/FCF

—N/A

P/B

0.9x82.5

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

—N/A

RS 6M

—N/A

SMA 50/200

—N/A

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+2%21.7

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$558M

P/E (Forward)

-1.4x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of EIKN are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
EIKN	Eikon Therapeutics, Inc.(you)	$558M	13	STRONG SELL
ARVN	Arvinas, Inc.	$570M	14	STRONG SELL
PROK	ProKidney Corp.	$547M	11	STRONG SELL
TRAX	First Tracks Biotherapeutics, Inc.	$552M	10	STRONG SELL
EDIT	Editas Medicine, Inc.	$526M	10	STRONG SELL
FULC	Fulcrum Therapeutics, Inc.	$454M	13	STRONG SELL
SGP	SpyGlass Pharma, Inc.	$663M	14	STRONG SELL
BBOT	BridgeBio Oncology Therapeutics, Inc.	$708M	12	STRONG SELL
0IL8.L	Kyntra Bio, Inc.	$666M	14	STRONG SELL
KYTX	Kyverna Therapeutics, Inc.	$526M	18	STRONG SELL

Peer medians: ROE -22.6% · P/E 25.3x · Gross margin 44.3%

Eikon Therapeutics, Inc. (EIKN) — Stock Score Summary

Eikon Therapeutics, Inc. (EIKN) has a MoatMap StockRank of 13/100 based on Quality (33/100), Value (41/100), and Momentum (25/100) factor scores. The current signal is STRONG SELL. Lacks sufficient public market history, financial transparency, and alignment with our core macro themes to justify inclusion in a concentrated book.

Key Financial Metrics

Price	$9.61
Market Cap	$558M
P/E (Forward)	-1.41
Price/Book	0.86
Return on Invested Capital	-59.9%
Debt/Equity	46.28
Gross Margin	0.0%
Operating Margin	0.0%

Eikon Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Eikon Therapeutics, Inc.’s (EIKN) StockRank?: MoatMap’s StockRank for Eikon Therapeutics, Inc. (EIKN) is 13/100, with a Strong Sell signal. It is a composite of Quality (33), Value (41), and Momentum (25) factor ranks across MoatMap’s 20,000+ stock universe.
Does Eikon Therapeutics, Inc. have an economic moat?: Eikon Therapeutics, Inc. (EIKN) has a Quality factor score of 33/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Eikon Therapeutics, Inc. a buy, hold, or sell?: MoatMap’s current signal for Eikon Therapeutics, Inc. (EIKN) is Strong Sell, based on a StockRank of 13/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Eikon Therapeutics, Inc. in?: Eikon Therapeutics, Inc. (EIKN) operates in the Healthcare sector, specifically the Biotechnology industry (United States).